Tarsons Products Limited · NSE:TARSONS
Tarsons Products — Q1 FY2026 Earnings Presentation
28 slides from Tarsons Products's earnings presentation, Aug 12, 2025
Slide 1: Cover letter to BSE and NSE
An ISO 9001 & ISO 13485 Certified Company Date: 12th August, 2025 To, To, BSE Limited (“BSE”), National Stock Exchange of India Limited (“NSE”) Corporate Relationship Department, “Exchange Plaza”, 5th Floor, 2nd Floor, New Trading Ring, Plot No. C/1, G Block, P.J. Towers, Dalal Street, Bandra-Kurla
Slide 2: Tarsons Products Limited Investor Presentation August 2025
TARSONS PRODUCTS LIMITED Investor Presentation August 2025 TRUST DELIVERED
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Tarsons Products Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secu
Slide 4: Q1FY26 Financial & Operational Highlights
Q1FY26 Financial & Operational Highlights
Slide 5: Q1FY26 Key Operational Highlights
Q1FY26 Key Operational Highlights Revenue (in Rs. Crs) Geography Mix Standalone Consolidated 34% 33% Standalone +10% +8% Q1FY25 Q1FY26 71 91 85 66% 67% 65 48 48 43 43 Consolidated 50% Q1FY25 50% 47% Q1FY26 53% 42 43 22 23 Q1FY25 Q1FY26 Q1FY25 Q1FY26 Domestic Overseas ➢ In Q1FY26, revenue grew by 9.9
Slide 6: Q1FY26 Standalone Financial Highlights
Q1FY26 Standalone Financial Highlights Revenue (in Rs. crs) EBITDA (in Rs. crs) Profit After Tax (in Rs. crs) Cash PAT# (in Rs. crs) +10% +31% +38% -45% 71.3 22.2 6.5 21.3 64.8 17.0 15.4 3.6 Q1FY25 Q1FY26 Q1FY25^ Q1FY26 Q1FY25 Q1FY26 Q1FY25 Q1FY26 Gross Margin (%) EBITDA Margin (%) PAT Margin (%) PA
Slide 7: Q1FY26 Consolidated Financial Highlights
Q1FY26 Consolidated Financial Highlights Revenue (in Rs. crs) EBITDA (in Rs. crs) Profit After Tax (in Rs. crs) Cash PAT# (in Rs. crs) +8% +32% +44% -56% 91.4 24.7 4.0 21.7 84.8 18.8 15.0 1.8 Q1FY25 Q1FY26 Q1FY25^ Q1FY26 Q1FY25 Q1FY26 Q1FY25 Q1FY26 Gross Margin (%) EBITDA Margin (%) PAT Margin (%) P
Slide 8: Bridge between Standalone & Consolidated PAT
Bridge between Standalone & Consolidated PAT (in Rs. crs) 3.6 -1.4 1.4 1.8 -1.0 -0.8 Q1FY26 Interest Income Interest paid to Amortisation on Nerbe PAT Q1FY26 Standalone PAT eliminated at bank by subsidiary intangible Consolidated PAT consolidation assets acquired 7
Slide 9: Management Commentary
Management Commentary Commenting on the performance, Mr. Aryan Sehgal, Promoter and Whole time Director of Tarsons, said: We are pleased to report a year-on-year revenue growth of 10% and an EBITDA growth of 31% on a standalone basis. Domestic revenues in Q1 FY26 saw a healthy uptick of approximatel
Slide 10: Q1FY26 Standalone Profit & Loss Statement
Q1FY26 Standalone Profit & Loss Statement Particulars (in Rs. Crs) Q1FY26 Q1FY25 Y-o-Y Revenue from Operations 71.3 64.8 9.9% Cost of Goods Sold 20.4 18.1 Gross Profit 50.9 46.8 8.7% Gross Margin (%) 71.4% 72.2% -80 bps Employee Cost 11.9 10.7 Other Expenses 16.8 19.1 EBITDA^ 22.2 17.0 30.6% EBITDA
Slide 11: Q1FY26 Consolidated Profit & Loss Statement
Q1FY26 Consolidated Profit & Loss Statement Particulars (in Rs. Crs) Q1FY26 Q1FY25 Y-o-Y Revenue from Operations 91.4 84.8 7.7% Cost of Goods Sold 29.3 27.7 Gross Profit 62.1 57.1 8.7% Gross Margin (%) 67.9% 67.4% 50 bps Employee Cost 17.9 16.1 Other Expenses 19.5 22.3 EBITDA 24.7 18.8 31.7% EBITDA
Slide 12: About Tarsons
TRUST DELIVERED
Slide 13: Tarsons – at a Glance
Tarsons – at a Glance One of the leading Indian labware company engaged in the designing, development, manufacturing and marketing of consumables, reusables and others (including benchtop equipment & instruments) Products used in laboratories across research organizations, academia institutes, pharm
Slide 14: Our Journey
Our Journey Established Product portfolio Commenced Pioneered the first fully manufacturing facility expansion & adding Established line for PCR production of Pipette robotic clean room expanding into depth in existing products in Jalan Tips, thereby creating a plant for manufacturing production of
Slide 15: Leading Indian Labware Supplier
Leading Indian Labware Supplier Trusted Brand for high quality Expertise in production of a wide range Ability to offer differentiated, user products in the plastic labware of labware products & amongst the friendly, reliable quality & cost-effective market with 40+ years vintage in the top 3 player
Slide 16: Our Competitive Edge
Our Competitive Edge Geographical Presence Brand & Quality Wide geographic reach through a Leading Indian supplier to the life sciences strong sales & distribution sector with strong brand recognition and network high-quality diversified products across varied customer segments. 03 04 State of Art F
Slide 17: Catering to diversified End User Industry
Catering to diversified End User Industry… Measures to strengthen customer relations Academic Institutes National Centre Indian Institute of Rain Forest KIIT Regular Feedback from Customers on quality, & Research for Biological Chemical Research Institute University 1 delivery & cost Sciences Techno
Slide 18: Our State-of-the-art Manufacturing Facilities
Our State-of-the-art Manufacturing Facilities… Key Highlights of the High Precision Manufacturing Process ✓ Vertically integrated manufacturing capabilities with design & development being carried out in-house ✓ Automated manufacturing with use of robotics & other technologies developed in collabora
Slide 19: Widespread Domestic Sales & Distribution network
…with widespread Domestic Sales & Distribution network… Comprehensive Pan-India Distribution Network Long-standing relationships with Distributors North: 17% of FY25 Domestic Sales East: 13% of FY25 Domestic Sales 42 Distributors 42 Distributors West: 29% of FY25 Domestic Sales 23 Distributors South
Slide 20: Huge underlying Export Market Potential
…with huge underlying Export Market Potential… Huge Export Opportunity Market One of the very few players to have a Global Reach ✓ As of 31st March 2025, the company sold its products to 40+ countries via 45+ distributors Demand for plasticware expected to grow at 10% CAGR for developing ✓ Export op
Slide 21: Wide Range of High-Quality Products
…offering Wide Range of High-Quality Products… Our products are made from high-quality medical grade DMF registered resins which are selected to minimize additives & reduce potential leachable Consumables Reusables Others 55.5% of FY25 40.7% of FY25 3.8% of FY25 Revenues Revenues Revenues • Portfoli
Slide 22: Diversified product portfolio of Plastic Labware
…diversified product portfolio of Plastic Labware Centrifuge Sterile Media Pipette Tips Petri Dishes Cryo Vials Storage Vials Serological Pipette Tubes Bottles Consumables (55% of FY25 Sales) • Mostly used in culture Designed for use Disposable pipettes Suited to preparation Used for storage of Perf
Slide 23: Glimpse of our product portfolio & processes
Glimpse of our product portfolio & processes Video link – Click here Video link – Click here Video link – Click here Video link – Click here Video link – Click here For more information & videos please visit www.tarsons.com/video-new 22
Slide 24: Key Business Strategies
Key Business Strategies • Focus on branding & promotion to enhance visibility in the labware industry to increase brand awareness & loyalty • Manufacture New Products in the cell culture & robotic handled consumables and expand Enhance existing & expand into the import dominated markets of these pro
Slide 25: Experienced Board of Director & Managerial Team
Experienced Board of Director & Managerial Team Mr. Ramanathan Subramanian Suresh Prabhala Arun Kumar Sanjive Sehgal Non-Executive Director Non-Executive Nominee Director Chairman & Managing Director • Partner & COO at ADV Partners with 25 • Investment professional with 25+ • Chairman & Managing Dir
Slide 26: Contribution towards Environmental, Social & Governance
Contribution towards Environmental, Social & Governance Clean room conditions eliminates all chances of NO litigations faced for pollution or contamination Use of Medical Grade degradation of environment over the Plastics. Products are designed to past five years Productivity optimisation with use o
Slide 27: Key Takeaways
Key Takeaways Leading Indian manufacturer of Financial profile with Historical labware with an established brand strong EBITDA margins & high & focus on high-quality products ROCE Presence in an industry with Highly automated state-of-the-art double-digit growth potential and manufacturing facilitie
Slide 28: Thank You
Thank You Tarsons Products Limited Strategic Growth Advisors Private Limited CIN: L51109WB1983PLC036510 CIN: U74140MH2010PTC204285 Mr. Santosh Agarwal – Chief Financial Officer Mr. Sagar Shroff / Mr. Tanay Shah santosh@tarsons.in sagar.shroff@sgapl.net / tanay.shah@sgapl.net +91 98205 19303 / +91 98